Germany’s Boehringer Ingelheim has opened a €70 million biologics plant in Shanghai to do contract manufacturing targeted at China's growing appetite for…

Drugmakers are closing small-molecule plants, but Sanofi is taking the process even further—it will destroy an unused plant it spent about $118 million to…

Thermo Fisher Scientific is acquiring Patheon—the center of the consolidation that has swept through contract manufacturing—in a deal valued at $7.2 billion.

A U.S. generics manufacturing site that India’s Lupin picked up in its 2015 buyout of GAVIS Pharmaceuticals has now been significantly expanded as the…

The FDA has warned Vikshara Trading & Investments for its repeated efforts to keep inspectors from getting a look into its filthy plant.

The FDA has cited an Aurobindo sterile manufacturing plant in India for not doing everything it can to prevent contamination, according to a new report.

Emergent BioSolutions is one of the vaccine producers that the federal government can tap in case of a virus pandemic.

India’s Wockhardt saw its losses widen last year as its burgeoning regulatory issues with the FDA continue to chainsaw away at its finances.

The on-again, off-again $215 million expansion of an Eli Lilly biologics plant in Ireland is on again.

Supply Chain